{"id":"retpamulin-ointment-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site pruritus"},{"rate":null,"effect":"Contact dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Retpamulin is a pleuromutilin antibiotic that selectively targets bacterial ribosomes, specifically the 50S subunit, to inhibit protein synthesis. This mechanism is bacteriostatic, stopping bacterial growth rather than directly killing the organisms. The drug has selective activity against gram-positive bacteria and some gram-negative organisms, making it suitable for topical skin infections.","oneSentence":"Retpamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:25.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Impetigo (non-bullous and bullous forms)"},{"name":"Secondarily infected traumatic skin lesions"}]},"trialDetails":[{"nctId":"NCT00852540","phase":"PHASE3","title":"Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-04","conditions":"Skin Infections, Bacterial","enrollment":410}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":97,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Retpamulin Ointment, 1%","genericName":"Retpamulin Ointment, 1%","companyName":"Stiefel, a GSK Company","companyId":"stiefel-a-gsk-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Retpamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth. Used for Impetigo (non-bullous and bullous forms), Secondarily infected traumatic skin lesions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}